NCT02975115View on ClinicalTrials.gov

Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization

UnknownOBSERVATIONAL
Enrollment

102

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2018

Conditions
Chronic Myelocytic Leukemia
Interventions
OTHER

RQ-PCR RNA Analysis

Conventional Q-RT-PCR every 3 months

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Seoul St. Mary's Hospital

OTHER